The PCAC voted six peptides onto the 503A list. What happens next.

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee sat at White Oak and worked through seven peptides. BPC-157, KPV, TB-500 and MOTS-c on the first day. Emideltide, semax and epitalon on the second. By the end of it the committee had recommended six of the seven for the 503A bulk drug substances list, which is the list that decides what a compounding pharmacy is allowed to build a preparation from.

That is the headline, and it travelled fast. Three things sit underneath it: the committee voted against its own staff's recommendation, it did so by margins of one and two votes, and a PCAC recommendation is not a rule. If you run a 503A pharmacy, the practical question is what changes now, and the answer is that almost nothing does yet.

What the committee actually did

FDA's own reviewers went into the meeting recommending against all seven substances. That matters, because the committee usually agrees with them. Here it did not, on six out of seven, and the votes were tight enough that a couple of people changing their minds would have flipped most of them.

Read the emideltide line next to the other six. One substance out of seven went the other way on a 7 to 6 split with an abstention. The committee was not waving these through. It was split down the middle on all of them and landed on different sides by a vote or two.

Why "recommended" is not "allowed"

The PCAC advises. It does not legislate, and the FDA is not required to follow it. What happens next is a process, and it is a slow one.

FDA takes the recommendations and the public comment from the meeting, and then decides whether to open notice-and-comment rulemaking. If it does, that process has historically run something like eight to twelve months before a substance is formally on the 503A list. Separately, the addition has to be signed off at the department level, which puts it on the desk of the Secretary of Health and Human Services.

So there are three gates after the vote, and the vote is only the first one. Any of them can end differently than the July meeting suggests.

What this means if you run a 503A

The short version: your legal position on 25 July was the same as it was on 22 July. Category 2 substances are still Category 2 until a rule says otherwise. Compounding from them in the meantime carries the same regulatory exposure it did before the meeting. A committee recommendation does not change that.

What did change is the direction of travel, and that is worth preparing for rather than acting on.

Get your sourcing question answered now, not later

If these substances do land on the list, the constraint moves immediately to bulk drug substance supply: an API from a registered facility, with a certificate of analysis and documentation that will hold up in an inspection. Pharmacies that start that conversation before the rule publishes will be months ahead of those that wait. This is the part of the timeline you control.

Decide your evidence posture before a patient asks

Six favourable votes will be read by a lot of people as an endorsement of these compounds, and your prescribers will hear that reading before they hear yours. It is worth writing down now, in plain language, what the research behind each of these actually is, and where it stops. For most of them it stops well before controlled human trials. BPC-157, to take the one with the most attention, still has no FDA-approved human indication and no published human injectable dose. That was true before the vote and the vote did not change it.

Watch the docket, not the coverage

The signal that matters is whether FDA opens rulemaking, and what the proposed rule says when it does. Coverage of the vote will keep circulating for months and none of it moves your position. A Federal Register notice does.

Why the reviewers and the committee disagreed

There is a reason the FDA's reviewers said no to all seven and a reason the committee still said yes to six, and the two are not really in conflict. The reviewers were answering a narrow question about whether the safety and effectiveness data supports adding a substance to a list. Several committee members were answering a broader one about what happens to patients and prescribers if the list stays closed while these compounds continue to be sold as research-grade material, outside the pharmacy system and outside pharmaceutical manufacturing standards.

You can think the committee got that call right or wrong. But the split explains the margins. This was not a panel that found the evidence strong. It was a panel that decided, narrowly, that a pharmacy supply held to manufacturing standards was preferable to the research-grade supply that already exists without them.

That framing is going to shape the rulemaking, and it is worth understanding before you read the proposed rule.

Where we stand

Six peptides have a recommendation. One does not. Nothing is on the 503A list that was not on it in June. FDA has not opened rulemaking as of this writing, and until it does, the practical status of every one of these substances is unchanged.

We label all 57 peptides in the app with how much research actually exists behind each one, and we say plainly when the answer is very little. That grading did not move on 24 July either. A committee vote is a regulatory signal, not new evidence.